WO2000010547A2 - Nouvelle utilisation de derives taxoides - Google Patents

Nouvelle utilisation de derives taxoides Download PDF

Info

Publication number
WO2000010547A2
WO2000010547A2 PCT/EP1999/006292 EP9906292W WO0010547A2 WO 2000010547 A2 WO2000010547 A2 WO 2000010547A2 EP 9906292 W EP9906292 W EP 9906292W WO 0010547 A2 WO0010547 A2 WO 0010547A2
Authority
WO
WIPO (PCT)
Prior art keywords
carbon atoms
radical
radicals
alkyl
atoms
Prior art date
Application number
PCT/EP1999/006292
Other languages
English (en)
Other versions
WO2000010547A3 (fr
Inventor
Marie-Christine Bissery
Patricia Vrignaud
Simon Roberts
Clive Brealey
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP98115650A external-priority patent/EP0982028A1/fr
Priority to EEP200100082A priority Critical patent/EE200100082A/xx
Priority to AU57420/99A priority patent/AU5742099A/en
Priority to IL14123199A priority patent/IL141231A0/xx
Priority to BR9913071-8A priority patent/BR9913071A/pt
Priority to CA002341191A priority patent/CA2341191A1/fr
Priority to KR1020017002136A priority patent/KR20010079665A/ko
Priority to HU0104000A priority patent/HUP0104000A3/hu
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Priority to JP2000565869A priority patent/JP2002523364A/ja
Priority to EA200100250A priority patent/EA200100250A1/ru
Priority to SK235-2001A priority patent/SK2352001A3/sk
Priority to EP99944532A priority patent/EP1105119A2/fr
Priority to MXPA01001721A priority patent/MXPA01001721A/es
Publication of WO2000010547A2 publication Critical patent/WO2000010547A2/fr
Publication of WO2000010547A3 publication Critical patent/WO2000010547A3/fr
Priority to NO20010655A priority patent/NO20010655D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Definitions

  • the present invention relates a new use of taxoid derivatives. It relates more precisely to a method for treating abnormal cell proliferation of different resistant cell lines expressing multidrug resistance P-glycoprotein. This type of cells are representative of colon cancer cells.
  • the present invention is related to the treatment of abnormal cell proliferation of different resistant cell lines expressing multidrug resistance P-glycoprotein and is also related to the treatment of abnormal cell proliferation of different resistant cell lines expressing multidrug resistance P- glycoprotein and is also related to the treatment of colon tumors of mammals including men by administrating a compound of general formula (I) or a pharmaceutically acceptable salt or solvante thereof :
  • Z represents a hydrogen atom or a radical of general formula :
  • R represents a benzoyl radical optionally substituted with one or more identical or different atoms or radicals chosen from halogen atoms and alkyl radicals containing 1 to 4 carbon atoms, alkoxy radicals containing 1 to 4 carbon atoms or trifluoromethyl radicals, a thenoyl or furoyl radical or a radical R 2 -O-CO- in which R 2 represents :
  • bicycloalkyl radical containing 7 to 10 carbon atoms these radicals being optionally substituted with one or more substituents chosen from halogen atoms and hydroxyl radicals, alkoxy radicals containing 1 to 4 carbon atoms, dialkylamino radicals in which each alkyl portion contains 1 to 4 carbon atoms, piperidino or morpholino radicals, 1-piperazinyl radicals (optionally substituted at position 4 with an alkyl radical containing 1 to 4 carbon atoms or with a phenylalkyl radical in which the alkyl portion contains 1 to 4 carbon atoms), cycloalkyl radicals containing 3 to 6 carbon atoms, cycloalkenyl radicals containing 4 to 6 carbon atoms, phenyl radicals (optionally substituted with one or more atoms or radicals chosen from halogen atoms and alkyl radicals containing 1 to 4 carbon atoms or alkoxy radicals containing 1 to 4 carbon atom
  • R 3 represents an unbranched or branched alkyl radical containing 1 to 8 carbon atoms, an unbranched or branched alkenyl radical containing 2 to 8 carbon atoms, an unbranched or branched alkynyl radical containing 2 to 8 carbon atoms, a cycloalkyl radical containing 3 to 6 carbon atoms, a phenyl or ⁇ - or ⁇ -naphthyl radical optionally substituted with one or more atoms or radicals chosen from halogen atoms and alkyl, alkenyl, alkynyl, aryl, aralkyl, alkoxy, alkylthio, aryloxy, arylthio, hydroxy
  • R 4 represents an alkoxy radical containing 1 to 6 carbon atoms in an unbranched or branched chain, an alkenyloxy radical containing 3 to 6 carbon atoms in an unbranched or branched chain, an alkynyloxy radical containing 3 to 6 carbon atoms in an unbranched or branched chain, a cycloalkyloxy radical containing 3 to 6 carbon atoms or a cycloalkenyloxy radical containing 4 to 6 carbon atoms, these radicals being optionally substituted with one or more halogen atoms or with an alkoxy radical containing 1 to 4 carbon atoms, an alkylthio radical containing 1 to 4 carbon atoms or a carboxyl radical, an alkyloxycarbonyl radical in which the alkyl portion contains 1 to 4 carbon atoms, a cyano or carbamoyl radical or an N-alkylcarbamoyl or N,N-dialkylcarbamoyl radical in which each alkyl
  • the aryl radicals which can be represented by R 3 are phenyl or ⁇ - or ⁇ -naphthyl radicals optionally substituted with one or more atoms or radicals chosen from halogen atoms (fluorine, chlorine, bromine, iodine) and alkyl, alkenyl, alkynyl, aryl, arylalkyl, alkoxy, alkylthio, aryloxy, arylthio, hydroxyl, hydroxyalkyl, mercapto, formyl, acyl, acylamino, aroylamino, alkoxycarbonylamino, amino, alkylamino, dialkylamino, carboxyl, alkoxycarbonyl, carbamoyl, dialkylcarbamoyl, cyano, nitro and trifluoromethyl radicals, on the understanding that the alkyl radicals and the alkyl portions of the other radicals contain 1 to 4 carbon atoms
  • the radicals R 4 and R 5 which may be identical or different, represent unbranched or branched alkoxy radicals containing 1 to 6 carbon atoms, optionally substituted with a methoxy, ethoxy, ethylthio, carboxyl, methoxycarbonyl, ethoxycarbonyl, cyano, carbamoyl, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-pyrrolidinocarbonyl or N-piperidinocarbonyl radical.
  • the present invention relates to the products of general formula (I) in which Z represents a hydrogen atom or a radical of general formula (II) in which R, represents a benzoyl radical or a radical R 2 -O-CO- in which R 2 represents a tert-butyl radical and R 3 represents an alkyl radical containing 1 to 6 carbon atoms, an alkenyl radical containing 2 to 6 carbon atoms, a cycloalkyl radical containing 3 to 6 carbon atoms, a phenyl radical optionally substituted with one or more identical or different atoms or radicals chosen from halogen atoms (fluorine, chlorine) and alkyl (methyl), alkoxy (methoxy), dialkylamino (dimethylamino), acylamino (acetylamino), alkoxycarbonylamino (tert-butoxycarbonylamino) or trifluoromethyl radicals, or a 2- or 3-furyl, 2- or 3-thieny
  • the present invention relates to the products of general formula (I) in which Z represents a hydrogen atom or a radical of general formula (II) in which R, represents a benzoyl radical or a radical R 2 -O-CO- in which R- j represents a tert-butyl radical and R 3 represents an isobutyl, isobutenyl, butenyl, cyclohexyl, phenyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-thiazolyl, 4-thiazolyl or 5-thiazolyl radical, and R 4 and R 5 , which may be identical or different, each represent a methoxy, ethoxy or propoxy radical.
  • R 3 represents a phenyl radical and Ri represents a ter-butoxycarbonyl radical
  • R-t and R 5 which may be identical or different, represent a methoxy, ethoxy or propoxy radical.
  • the present invention relates to 4 ⁇ -acetoxy-2 ⁇ - benzoyloxy-5 ⁇ ,20-epoxy- 1 ⁇ -hydroxy-7 ⁇ , 1 O ⁇ -dimethoxy-9-oxo- 11 -taxen- 13 ⁇ -yl (2R,3S)-3 tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate of formula (la)
  • R-X (IV) in which R represents a radical as defined above and X represents a reactive ester residue such as a sulphuric or sulphonic ester residue or a halogen atom, to give a product bearing the unit -OR in position 10 and silyl groups in positions 7 and 13.
  • the silyl protecting groups are replaced with hydrogen atoms to give a compound still bearing the group -OR in position 10 and OH groups in positions 7 and 13.
  • the latter derivative is etherified selectively in position 7 by reaction with the derivative of formula IV to give the derivative of formula (I) in which Z is equal to hydrogen.
  • the final step consists in esterifying in position 13, according to a process which is known per se, the derivatives of formula (la), in which Z represents hydrogen, in the presence of a ⁇ -lactam according, for example, to the process described in patent EP 617,018, or in the presence of an oxazolidine as described, for example, in patent WO 96/30355 mentioned above.
  • the final step, which allows the desired compound of formula (la) to be obtained, is carried out on the intermediate compound obtained above, by the action of activated Raney nickel.
  • the action of the reagent formed in situ from sulphoxide of general formula (V), preferably dimethyl sulphoxide and acetic anhydride, is carried out in the presence of acetic acid or an acetic acid derivative such as a haloacetic acid, at a temperature of between 0 and 50°C.
  • the action of the activated Raney nickel in the presence of an aliphatic alcohol or an ether is carried out at a temperature of between -10 and 60°C.
  • A represents hydrogen or a side chain of formula (Ha) below :
  • G represents a protecting group for the hydroxyl function
  • R, and R 3 have the same meaning as in formula (II) or an oxazolidine unit of formula (Id) :
  • R, and R 3 have the same meaning as in formula (II)
  • R a and R b which may be identical or different, represent hydrogen or alkyl, aryl, halo, alkoxy, arylalkyl, alkoxyaryl, haloalkyl, haloaryl, it being possible for the substituents optionally to form a 4- to 7-membered ring.
  • 10-deacetylbaccatin as starting material, i.e. the product of formula (III), which allows appreciable economy as regards the process and moreover avoids the intermediate protection and deprotection steps necessary in the old processes.
  • ethers and preferably ethers such as methoxymethyl ether, 1-ethoxyethyl ether, benzyloxymethyl ether, p-methoxybenzyloxymethyl ether, benzyl ethers optionally substituted with one or more groups such as methoxy, chloro, nitro, 1-methyl- 1 -methoxy ethyl ether, 2-(trimethylsilyl)ethoxymethyl ether, tetrahydropyranyl ether and silyl ethers such as trialkylsilyl ethers, • carbon
  • radicals R a and R b of general formula (lib) are chosen from those described in patent WO 94/07878 and the derivatives more particularly preferred are those in which R a is hydrogen and R b is a p-methoxyphenyl radical.
  • the alkylating agent is chosen from : • alkyl halides, and preferably from alkyl iodides (RI)
  • alkyl sulphates such as methyl sulphate
  • oxoniums such as trialkyloxonium boric salts, in particular trimethyloxonium tetrafluoroborate (Me 3 OBF 4 ).
  • Methyl iodide is preferably used.
  • the alkylating agent is used in the presence of an anionization agent such as one or more strong bases, in anhydrous medium.
  • alkali metal hydrides such as sodium or potassium hydride
  • alkali metal alkoxides such as potassium tert-butoxide
  • methyl iodide in the presence of potassium hydride.
  • the reaction is preferably carried out in an organic medium which is inert under the reaction conditions.
  • organic medium which is inert under the reaction conditions.
  • solvents it is preferred to use :
  • polar aprotic solvents such as dimethylformamide, or aromatic solvents such as toluene
  • alkylesters such as ethylacetate.
  • a molar ratio between the anionization agent and the substrate of greater than 2 and preferably between 2 and 20.
  • a molar ratio between the alkylating agent and the substrate of greater than 2 and preferably between 2 and 40.
  • reaction temperature between -30°C and 80°C.
  • reaction time advantageously ranges between a few hours and 48 hours depending on the reagents chosen.
  • the process then proceeds, in a known manner, to the esterification step according, for example, to the processes described in patents EP 617,018 or WO 96/30355 mentioned above.
  • the procedure first begins with the dialkylation of 10-deacetylbaccatin, using an alkylating agent in the presence of a strong base, in a second step, the 10-deacetylbaccatin dietherified in positions 7 and 10 is coupled, in position 13, with a suitably protected ⁇ -lactam in the presence of an activating agent chosen from tertiary amines and metal bases which ensure the formation of an alkoxide in position 13. Deprotection of the side chain is then achieved by the action of an inorganic or organic acid.
  • the procedure first begins with the dialkylation of 10-deacetylbaccatin, using an alkylating agent in the presence of a strong base, in a second step, the 10-deacetylbaccatin dietherified in positions 7 and 10 is coupled, in position 13, with an oxazolidine in the presence of a coupling agent such as diimides in the presence of an activating agent such as dialkylaminopyridines. Opening of the oxazolidine is achieved by the action of an inorganic or organic acid.
  • the procedure begins with the esterification in position 13 of baccatin suitably protected in positions 7 and 10, with a ⁇ -lactam or an oxazolidine in the presence of a coupling agent and/or an activating agent as described in the above two processes.
  • the dietherification in positions 7 and 10 is carried out by an alkylating agent in the presence of a strong base. Deprotection of the side chain is then achieved by the action of an inorganic or organic acid.
  • the compounds of formula I have anti-tumor properties, more particularly, activity against tumors which are resistant to Taxol® and Taxotere®.
  • tumors include, for example, colon tumors which have an elevated expression of multidrug resistance P-glycoprotein.
  • Multi-drug resistance is the usual term relating to the resistance by a tumor against various compounds having differing structures and mechanisms of action.
  • Taxoids are generally known to be highly recognized by experimental tumors such as P388/DOX, a P388 murine leukemia cell line selected for doxorubicin (DOX) resistance, which express P-glycoprotein.
  • the compounds according to the present invention are less recognized by P388/DOX. More particularly, the compounds are less recognized than Taxotere®.
  • the compounds of formula (I) are mainly used for preparing a medecine for treating abnormal cell proliferation of cell lines expressing the multidrug resistance P-glycoprotein.
  • the compound of formula I are mainly used for preparing a medecine for treating colon cancer.
  • the compound and mainly compound of formula (I) where P and R 5 are each methoxy has the property to be active compared to the other known taxoids such as Taxol® or Taxotere® to treat the cancer cells lines expressing the multidrug resistance P-glycoprotein. It is also active against tumor cells resistant to
  • the product of formula (I) can be used concurrently with at least other therapeutic treatment. It is more preferably used with other therapeutic treatment comprising antineoplastic drugs, monoclonal antibodies, immunotherapies, radiotherapies, or biological response modifiers.
  • the product of formula (I) is preferably administered by parenteral administration such as intravenous, intraperitoneal, intramuscular or subcutaneous administration.
  • Product of formula (la) is a potent anti-cancer agent in pre-clinical models. In vitro antiproliferative properties on resistant cell lines
  • Docetaxel was found to be cross-resistant to cell lines expressing the multidrug resistance P-glycoprotein (RIGEL I. and HORWITZ S.B., Studies with RP 56976 (Taxotere®: a semisynthtetic analogue of Taxol, J. Natl. Cancer Inst, 83, 288-291, 1991).
  • the cytotoxicity of product la was examined against different resistant cell lines expressing the multidrug resistance P-glycoprotein, in comparison with docetaxel after 4 days of continuous exposure using standard methods.
  • the resistance factor was calculated by dividing the IC50 value obtained on resistant cells by the IC50 value obtained on sensitive cells.
  • product of formula la was found more active than docetaxel on all the resistant tumor cell lines which have been evaluated. Interestingly, product of formula la was found minimally cross-resistant (resistance factor: 1.8 to 4.3) in the P388/TXT, P388 NCR, HL60/TAX and Calcl8/TXT cell lines that are moderately cross- resistant to docetaxel (resistance factor: 4.8 to 23.5) and which could be more representative of the clinical situation.
  • Product of formula la was also evaluated on the murine P388/CPT5 cell line with acquired resistance to camptothecin that do not express the P-glycoprotein. A strong decrease in the cross-resistance was found for product of formula la and docetaxel (resistance factor: 4.8 and 10.5) as compared to camptothecin (resistance factor: 286). This result suggests a potential application of product of formula la in the treatment of tumors with acquired resistance to camptothecin derivatives.
  • the antiproliferative properties of the product of formula la and docetaxel were examined on the human colon adenocarcinoma CaCo-2 cell line (ATCC HTB37) that was shown to present a basal level of expression of P-glycoprotein encoded by the mdrl gene.
  • the methodology was used, i.e., 96 well plates, time of contact of the drugs (96 hours) and neutral red coloration of viable cell. Results expressed as IC50, were summarized in the next table.
  • Product of formula la is cytotoxic on CaCo-2 cells with IC50 included in the range described on the other human cell line tested, i.e., HL60, Calcl ⁇ and KB (see previous paragraph).
  • IC50 included in the range described on the other human cell line tested, i.e., HL60, Calcl ⁇ and KB (see previous paragraph).
  • docetaxel displays a higher IC50 on CaCo-2 cells, corresponding to 4.9 times the values observed with Product of formula la. Therefore, the higher antiproliferative activity of Product of formula la, compared to docetaxel, on CaCo-2 cells is in agreement with a lower recognition of Product of formula la than docetaxel by the P-glycoprotein intrinsically expressed by this cell line.
  • T/C tumor growth inhibition
  • T/C > 42 %, - is inactive
  • a T/C ⁇ _42 %, + is the minimum level for activity.
  • a T/C ⁇ 10 %, ++ is considered as a high antitumor activity level which justifies further development (DN-2 level).
  • DN-2 level the two following end points were also used: - tumor growth delay, T-C, where T and C are the median times in days required for the treatment group and the control group tumors to reach a predetermined size (750 to l500 mg).
  • regressions can be either partial (more than 50 % reduction in tumor mass) or complete. Complete regressions are included in the partial regressions.
  • the end point used for assessing activity in intraperitoneally implanted leukemia was percent increase in host life span (% ILS), calculated in relation to median day of death.
  • the NCI criteria for activity are as follows:
  • Toxicity was based on drug deaths (> 10 %) or a weight loss nadir > 20 %. Docetaxel was used for comparison trials when needed. Colon tumors
  • Colon 51 Product of formula la was administered i.v. on day 4, 6, 8. At the HNTD (9.3 mg/kg/injection), it was found highly active with a 0 % T/C and a 2.6 log cell kill. The dosage below yielded a 2.2 log cell kill. Docetaxel was also found highly active with a 3.1 log cell kill.
  • HNTD highest nontoxic dose
  • bwl body weight loss
  • DD drug death
  • bwl body weight loss.
  • HNTD highest nontoxic dose
  • bwl body weight loss
  • DD drug death
  • TFS tumor free survivors observed on day 139.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne une nouvelle utilisation de dérivés taxoïdes et plus précisément une méthode de traitement de la prolifération cellulaire anormale de différentes lignées cellulaires exprimant de la P-glycoprotéine résistant à l'action de plusieurs médicaments. Ce type de cellules est représentatif des cellules du cancer du côlon. Les produits de l'invention peuvent également être utilisés pour le traitement du cancer du côlon chez les mammifères dont l'homme.
PCT/EP1999/006292 1998-08-20 1999-08-18 Nouvelle utilisation de derives taxoides WO2000010547A2 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
MXPA01001721A MXPA01001721A (es) 1998-08-20 1999-08-18 Nuevo uso de derivados de taxoide.
HU0104000A HUP0104000A3 (en) 1998-08-20 1999-08-18 New use of taxoid derivatives
IL14123199A IL141231A0 (en) 1998-08-20 1999-08-18 New use of taxoid derivatives
BR9913071-8A BR9913071A (pt) 1998-08-20 1999-08-18 Uso de um composto derivado de taxóide
JP2000565869A JP2002523364A (ja) 1998-08-20 1999-08-18 タキソイド誘導体の新規な使用
KR1020017002136A KR20010079665A (ko) 1998-08-20 1999-08-18 탁소이드 유도체의 신규 용도
AU57420/99A AU5742099A (en) 1998-08-20 1999-08-18 New use of taxoid derivatives
EEP200100082A EE200100082A (et) 1998-08-20 1999-08-18 Taksoidi derivaatide kasutamine ravimi valmistamiseks, mis on ette nähtud rakkude ebaloomuliku proliferatsiooni raviks laiaspektrilise ravimresistentsusega P-glükoproteiini ekspresseerivates rakuliinides
CA002341191A CA2341191A1 (fr) 1998-08-20 1999-08-18 Nouvelle utilisation de derives taxoides
EA200100250A EA200100250A1 (ru) 1998-08-20 1999-08-18 Новое применение таксоидных производных
SK235-2001A SK2352001A3 (en) 1998-08-20 1999-08-18 New use of taxoid derivatives
EP99944532A EP1105119A2 (fr) 1998-08-20 1999-08-18 Nouvelle utilisation de derives taxoides
NO20010655A NO20010655D0 (no) 1998-08-20 2001-02-07 Ny anvendelse av taxoidderivater

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP98115650A EP0982028A1 (fr) 1998-08-20 1998-08-20 Nouvelle utilisation de dérivés de taxoides
EP98115650.8 1998-08-20
US12384399P 1999-03-11 1999-03-11
US60/123,843 1999-03-11

Publications (2)

Publication Number Publication Date
WO2000010547A2 true WO2000010547A2 (fr) 2000-03-02
WO2000010547A3 WO2000010547A3 (fr) 2000-06-29

Family

ID=26149552

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/006292 WO2000010547A2 (fr) 1998-08-20 1999-08-18 Nouvelle utilisation de derives taxoides

Country Status (15)

Country Link
EP (1) EP1105119A2 (fr)
JP (1) JP2002523364A (fr)
KR (1) KR20010079665A (fr)
CN (1) CN1313764A (fr)
AU (1) AU5742099A (fr)
BG (1) BG105273A (fr)
CA (1) CA2341191A1 (fr)
EE (1) EE200100082A (fr)
HU (1) HUP0104000A3 (fr)
IL (1) IL141231A0 (fr)
MX (1) MXPA01001721A (fr)
NO (1) NO20010655D0 (fr)
SK (1) SK2352001A3 (fr)
TR (1) TR200100575T2 (fr)
WO (1) WO2000010547A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8927592B2 (en) 2009-10-29 2015-01-06 Aventis Pharma Sa Antitumoral use of cabazitaxel

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2922107B1 (fr) * 2007-10-10 2010-02-26 Aventis Pharma Sa Nouvelles compositions a base de taxoides

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010169A1 (fr) * 1992-10-30 1994-05-11 Rhone-Poulenc Rorer S.A. Procede de preparation de derives du taxane
WO1996030355A1 (fr) * 1995-03-27 1996-10-03 Rhone-Poulenc Rorer S.A. Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
WO1996032387A1 (fr) * 1995-04-14 1996-10-17 Rhone-Poulenc Rorer S.A. Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010169A1 (fr) * 1992-10-30 1994-05-11 Rhone-Poulenc Rorer S.A. Procede de preparation de derives du taxane
WO1996030355A1 (fr) * 1995-03-27 1996-10-03 Rhone-Poulenc Rorer S.A. Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
WO1996032387A1 (fr) * 1995-04-14 1996-10-17 Rhone-Poulenc Rorer S.A. Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8927592B2 (en) 2009-10-29 2015-01-06 Aventis Pharma Sa Antitumoral use of cabazitaxel
US10583110B2 (en) 2009-10-29 2020-03-10 Sanofi Mature Ip Antitumoral use of cabazitaxel
US10716777B2 (en) 2009-10-29 2020-07-21 Sanofi Mature Ip Antitumoral use of cabazitaxel

Also Published As

Publication number Publication date
HUP0104000A2 (hu) 2002-04-29
AU5742099A (en) 2000-03-14
HUP0104000A3 (en) 2003-01-28
CA2341191A1 (fr) 2000-03-02
TR200100575T2 (tr) 2001-07-23
NO20010655L (no) 2001-02-07
WO2000010547A3 (fr) 2000-06-29
SK2352001A3 (en) 2001-07-10
MXPA01001721A (es) 2005-06-03
IL141231A0 (en) 2002-03-10
JP2002523364A (ja) 2002-07-30
KR20010079665A (ko) 2001-08-22
EE200100082A (et) 2002-06-17
EP1105119A2 (fr) 2001-06-13
NO20010655D0 (no) 2001-02-07
CN1313764A (zh) 2001-09-19
BG105273A (en) 2001-11-30

Similar Documents

Publication Publication Date Title
AP753A (en) Novel taxoids, preparation thereof and pharmaceutical compositions containing same.
PL189311B1 (pl) Nowe taksoidy, sposób ich wytwarzania i kompozycje farmaceutyczne zawierające te związki
BG99713A (bg) Нови таксоиди,тяхното получаване и фармацевтичнисъстави,които ги съдържат
US6346543B1 (en) Use of a taxoid to treat abnormal cell proliferation in the brain
US5547981A (en) Taxol-7-carbazates
AP1023A (en) Taxoids, preparation thereof and pharmaceutical compositions containing same.
EP0982028A1 (fr) Nouvelle utilisation de dérivés de taxoides
WO2000010547A2 (fr) Nouvelle utilisation de derives taxoides
CZ310997A3 (cs) Taxoidy, způsob jejich přípravy a farmaceutické kompozice tyto taxoidy obsahující
Bouchard et al. Novel taxanes: cabazitaxel case study
US6403634B1 (en) Use of taxoid derivatives
WO2000066113A1 (fr) Methode de traitement d'une proliferation de cellules anormales dans le cerveau
CZ2001603A3 (cs) Způsob výroby léčivých obrazů GA/MO, při kterém léčivý obraz vzniká přímo na fólii (1,2) na bázi otisku, a to tak, že se spodní fólie (1) položí na podkladovou plochu (4) přičemž na vrchní stranu fólie (1) se nanesou barvy (3), na ně se položí vrchní fólie (2) a na takto připravené fólie (1,2) se působí tlakem, přičemž ve spodní fólii (1) i vrchní fólii (2) se vyberou nejaktivnější partie (9), které se označí, vystřihnou a následné zapaspartují.
JP2003520792A (ja) 抗腫瘍活性及び抗脈管形成活性を有する半合成タキサン類
CN113599370B (zh) 8-oh-dpat及其衍生物在制备抗肿瘤药物中的应用
EP0982027A1 (fr) Dérivés taxoides pour traiter les proliférations cellulaires anormales du cerveau
EP1140064A2 (fr) Nouvelle utilisation de derives de taxoides
CA2365776A1 (fr) Methode de traitement d'une proliferation de cellules anormales dans le cerveau
Piccart Taxol and Taxotere: new drugs of interest in the treatment of advanced ovarian cancer
Einstein MJ PICCART
MXPA01001683A (en) New use of taxoid derivatives

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99809900.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AU BA BB BG BR CA CN CR CU CZ DM EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO RU SG SI SK SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AU BA BB BG BR CA CN CR CU CZ DM EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO RU SG SI SK SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 141231

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: P-80/01

Country of ref document: YU

WWE Wipo information: entry into national phase

Ref document number: 1999944532

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/001721

Country of ref document: MX

Ref document number: PV2001-603

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 2352001

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 2341191

Country of ref document: CA

Ref document number: 2341191

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 510039

Country of ref document: NZ

Ref document number: 1020017002136

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 1999 105273

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001/01414

Country of ref document: ZA

Ref document number: 57420/99

Country of ref document: AU

Ref document number: 200101414

Country of ref document: ZA

Ref document number: IN/PCT/2001/00163/DE

Country of ref document: IN

Ref document number: 2001/00575

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 200100250

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 20010217

Country of ref document: UZ

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1200100267

Country of ref document: VN

WWP Wipo information: published in national office

Ref document number: 1999944532

Country of ref document: EP

Ref document number: PV2001-603

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020017002136

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1999944532

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV2001-603

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1020017002136

Country of ref document: KR